Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 717-735 , December 2007

Lenalidomide in multiple myeloma

References 

  1. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. American Journal of Hematology. 1990;33(2):86–89
  2. Alexanian R, Bergsagel DE, Migliore PJ, et al. Melphalan therapy for plasma cell myeloma. Blood. 1968;31(1):1–10
  3. Alexanian R, Dimopoulos MA, Delasalle K, et al. Primary dexamethasone treatment of multiple myeloma. Blood. 1992;80(4):887–890
  4. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. The Journal of the American Medical Association. 1969;208(9):1680–1685
  5. Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplantation. 2001 May;27(10):1037–1043
  6. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. The New England Journal of Medicine. 2003 May 8;348(19):1875–1883
  7. Alexanian R, Weber D, Anagnostopoulos A, et al. Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Seminars in Hematology. 2003;40(4 supplement 4):3–7
  8. Chanan-Khan A, Miller KC. Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma. Leukemia & Lymphoma. 2005 Jul;46(7):1103–1104
  9. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Annals of Oncology. 2001 July 1;12(7):991–995
  10. Orlowski RZ, Peterson BL, Sanford B et al. Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 797.
  11. Palumbo A, Ambrosini MT, Benevolo G et al. Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 407.
  12. Popat R, Williams C, Cook M et al. A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3542.
  13. Chanan-Khan AA, Miller KC, McCarthy P, et al. VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) is an effective initial therapy with high response rates for patients with treatment naïve multiple myeloma (MM). Blood. 2004;104:
  14. Hussein MA, Baz R, Srkalovic G, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. [see comment] Mayo Clinic Proceedings. 2006;81(7):889–895
  15. Jagannath S, Durie BG, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology. 2005;129(6):776–783
  16. Mateos M-V, Hernandez J-M, Hernandez M-T, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006 October 1;108(7):2165–2172
  17. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. British Journal of Haematology. 2005;129(6):755–762
  18. Offidani M, Corvatta L, Piersantelli M-N, et al. Thalidomide, dexamethasone, pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood. 2006;108:2159–2164
  19. Wang M, Delasalle K, Giralt S et al. Rapid Control of Previously Untreated Multiple Myeloma with Bortezomib-Thalidomide-Dexamethasone Followed by Early Intensive Therapy. ASH Annual Meeting Abstracts. 2005 November 16, 2005; 106(11): 784.
  20. Zervas K, Dimopoulos MA, Hatzicharissi E, et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Annals of Oncology. 2004;15(1):134–138
  21. Jakubowiak AJ, Al-Zoubi A, Kendall T et al. High Rate of Complete and near Complete Responses (CR/nCR) after Initial Therapy with Bortezomib (Velcade(V)), Doxil(D), Dexamethasone (VDD) Is Further Increased after Autologous Stem Cell Transplantation (ASCT). ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3093.
  22. Palumbo A, Bertola A, Musto P, et al. Oral melphalan, prednisone, thalidomide for newly diagnosed patients with myeloma. Cancer. 2005;104:1428–1433
  23. Boulin M, Blanchet F, Isambert N, et al. Thalidomide with or without dexamethasone for refractory multiple myeloma. Therapie. 2002;57(6):524–529
  24. Zangari M, Barlogie B, Jacobson J, et al. VTD regimen comprising Velcade (V) + Thalidomide (T) and added DEX (D) for non-responders to V + T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. Blood. 2003;102(11):
  25. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825–831
  26. Jakubowiak A, Friedman J, Kendall T, et al. A phase II study of combination of bortezomib, liposomal doxorubin, dexamethasone (VDD) as first line therapy for multiple myeloma. Journal of Clinical Oncology. 2006;24(18S):
  27. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Journal of Clinical Oncology. 2003;21:16–19
  28. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. [see comment] New England Journal of Medicine. 2005 Jun 16;352(24):2487–2498
  29. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. [see comment] New England Journal of Medicine. 2003;348(26):2609–2617
  30. Rajkumar SV, Blood E, Vesole D, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. [see comment] Journal of Clinical Oncology. 2006;24(3):431–436
  31. Rajkumar SV, Hussein M, Catalano J, et al. A randomized, double-blind, placebo-controlled trial of thalidomide plus dexamethasone versus dexamethasone alone as primary therapy for newly diagnosed multiple myeloma. 2006;108:795
  32. Jagannath S, Durie BGM, Wolf JL et al. Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 796.
  33. Anderson K, Richardson P, Chanan-Khan A, et al. Single-agent bortezomib in previously untreated multiple myeloma (MM): results of a phase II multicenter study. Journal of Clinical Oncology. 2006;24(18S):
  34. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. [see comment] Blood. 2005;106(13):4050–4053
  35. Knight R. IMiDs: a novel class of immunomodulators. Seminars In Oncology. 2005;32(4 supplement 5):S24–S30
  36. Lacy M, Gertz M, Dispenzieri A, et al. Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: response to therapy, time to progression, survival. Blood. 2006;108:
  37. Richardson P, Jagannath S, Hussein M et al. A Multicenter, Single-Arm, Open-Label Study To Evaluate the Efficacy and Safety of Single-Agent Lenalidomide in Patients with Relapsed and Refractory Multiple Myeloma; Prelininary Results. ASH Annual Meeting Abstracts. 2005 November 16, 2005; 106(11): 1565.
  38. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006;108(10):3458–3464
  39. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009). Journal of Clinical Oncology. 2006;24(18S):
  40. Zangari M TG, Zeldis J, Eddlemon P, et al. Results of phase I study of CC-5013 for the treatment of multiple myeloma (mm) patients who relapse after high dose chemotherapy (HDCT). Blood. 2001;775a
  41. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood. 2007 January 15;109(2):465–470
  42. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood. 2007 January 15;109(2):492–496
  43. Dimopoulos MA, Spencer A, Attal M et al. Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010). ASH Annual Meeting Abstracts. 2005 November 16, 2005; 106(11): 6.
  44. Weber D, Wang M, Chen C et al. Lenalidomide Plus High-Dose Dexamethasone Provides Improved Overall Survival Compared to High-Dose Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma (MM): Results of 2 Phase III Studies (MM-009, MM-010) and Subgroup Analysis of Patients with Impaired Renal Function. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3547.
  45. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002 October 16;100(9):3063–3067
  46. Muller GW, Chen R, Huang SY, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorganic & Medicinal Chemistry Letters. 1999 Jun 7;9(11):1625–1630
  47. Anderson KC. Lenalidomide and thalidomide: mechanisms of action – similarities and differences. Seminars in Hematology. 2005;42(4 supplement 4):S3–S8
  48. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99(12):4525–4530
  49. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96(9):2943–2950
  50. Fujita E, Jinbo A, Matuzaki H, et al. Akt phosphorylation site found in human caspase-9 is absent in mouse caspase-9. Biochemical and Biophysical Research Communications. 1999;264(2):550–555
  51. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. Journal of Biological Chemistry. 2002;277(19):16639–16647
  52. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nature Reviews Cancer. 2002;2(12):927–937
  53. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15(12):1950–1961
  54. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17(1):41–44
  55. Dredge K, Marriott JB, Macdonald CD, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer. 2002;87(10):1166
  56. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. The New England Journal of Medicine. 1999;341(21):1565–1571
  57. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. [see comment] Blood. 2001;98(1):210–216
  58. Breitkreutz I, Tai Y, Li X, et al. Lenalidomide and bortezomib induce osteoclast cytotoxicity and decrease BAFF secretion in osteoclasts in human multiple myeloma: clinical implications. 2006 ASCO Annual Meeting Proceedings Part I Journal of Clinical Oncology. 2006;24(18S):7606
  59. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, overcomes drug resistance in human multiple myeloma cells. Cancer Research. 2001;61(7):3071–3076
  60. Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 December 15;104(13):4188–4193
  61. Zeldis JB, Williams BA, Thomas SD, et al. S.T.E.P.S., a comprehensive program for controlling and monitoring access to thalidomide. Clinical Therapeutics. 1999 Feb;21(2):319–330
  62. Knight R. Lenalidomide and venous thrombosis in multiple myeloma. The New England Journal of Medicine. 2006;354(19):2079
  63. Palumbo A, Falco P, Falcone A et al. Oral Revlimid(R) Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 800.
  64. Zonder JA, Durie BGM, McCoy J et al. High Incidence of Thrombotic Events Observed in Patients Receiving Lenalidomide (L) + Dexamethasone (D) (LD) as First-Line Therapy for Multiple Myeloma (MM) without Aspirin (ASA) Prophylaxis. ASH Annual Meeting Abstracts. 2005 November 16, 2005; 106(11): 3455.
  65. Zonder JA, Barlogie B, Durie BGM, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood. 2006 July 1;108(1):403–404
  66. Rajkumar S, Jacobus S, Callander N, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. ASCO Annual Meeting Proceedings Part I Journal of Clinical Oncology. 2007;25(18S):LBA8025
  67. Darabi K, Kantamnei S, Wiernik PH. Lenalidomide-induced warm autoimmune hemolytic anemia. Journal of Clinical Oncology. 2006 December 10;24(35):e59
  68. Sviggum HP, Davis MDP, Rajkumar SV, et al. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Archives of Dermatology. 2006 October 1;142(10):1298–1302
  69. Kastritis E, Dimopoulos MA. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opinion on Pharmacotherapy. 2007;8(4):497–509
  70. Wang M, Knight R, Dimopoulos M et al. Lenalidomide in Combination with Dexamethasone Was More Effective Than Dexamethasone in Patients Who Have Received Prior Thalidomide for Relapsed or Refractory Multiple Myeloma. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3553.
  71. Knop S, Gerecke C, Topp MS et al. Lenalidomide (RevlimidTM), Adriamycin and Dexamethasone Chemotherapy (RAD) Is Safe and Effective in Treatment of Relapsed Multiple Myeloma – First Results of a German Multicenter Phase I/II Trial. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 408.
  72. Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Annals of Oncology. 2006;17(12):1766–1771
  73. Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. [see comment] Mayo Clinic Proceedings. 2005;80(12):1568–1574
  74. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia. 2004;18(4):856–863
  75. Morgan GJ, Schey S, Wu P et al. Lenolidamide (Revlimid), in Combination with Cyclophosphamide and Dexamethasone (CRD) Is an Effective Regimen for Heavily Pre-Treated Myeloma Patients. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3555.
  76. Richardson PG, Jagannath S, Avigan DE et al. Lenalidomide Plus Bortezomib (Rev-Vel) in Relapsed and/or Refractory Multiple Myeloma (MM): Final Results of a Multicenter Phase 1 Trial. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 405.
  77. Richardson P, Schlossman R, Munshi N et al. A Phase 1 Trial of Lenalidomide (REVLIMID(R)) with Bortezomib (VELCADE(R)) in Relapsed and Refractory Multiple Myeloma. ASH Annual Meeting Abstracts. 2005 November 16, 2005; 106(11): 365.
  78. Coleman M, Leonard J, Lyons L, et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leukemia & Lymphoma. 2002;43(9):1777–1782
  79. Niesvizky R, Jayabalan D, Furst JR, et al. Clarithromycin, lenalidomide and dexamethasone combination therapy as primary treatment of multiple myeloma. Journal of Clinical Oncology. 2006;24(18S):7545
  80. Roy V, Leif BP, Jacob A et al. Melphalan (M), Prednisone (P) and Lenalidomide (R) Combination (MPR) for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. ASH Annual Meeting Abstracts. 2006 November 16, 2006; 108(11): 3558.
  81. Gertz MA, Rajkumar SV. Primary systemic amyloidosis. Current Treatment Options in Oncology. 2002;3:261–271
  82. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, colchicine versus colchicine only. American Journal of Medicine. 1996;100(3):290–298
  83. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, melphalan, prednisone, colchicine. [see comment] New England Journal of Medicine. 1997;336(17):1202–1207
  84. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Annals of Internal Medicine. 2004;140(2):85–93
  85. Palladini G, Perfetti V, Perlini S, et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood. 2005;105(7):2949–2951
  86. Zangari M, Barlogie B, Jacobson J, et al. Revimid 25 mg (REV 25) × 20 versus 50 mg (REV 50) × 10 q 28 days with bridging of 5 mg × 10 versus 10 mg × 5 as post-transplant salvage therapy for multiple myeloma (MM). Blood. 2003;102(11):

PII: S1521-6926(07)00069-2

doi: 10.1016/j.beha.2007.09.002

Best Practice & Research Clinical Haematology
Volume 20, Issue 4 , Pages 717-735 , December 2007

Article Tools